EP1546714A4 - Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain - Google Patents

Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain

Info

Publication number
EP1546714A4
EP1546714A4 EP02799873A EP02799873A EP1546714A4 EP 1546714 A4 EP1546714 A4 EP 1546714A4 EP 02799873 A EP02799873 A EP 02799873A EP 02799873 A EP02799873 A EP 02799873A EP 1546714 A4 EP1546714 A4 EP 1546714A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
therapy
compositions
methods
human cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02799873A
Other languages
German (de)
English (en)
Other versions
EP1546714A1 (fr
Inventor
Wadih Arap
Mikhail G Kolonin
Paul J Mintz
Renata Pasqualini
Amado J Zurita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/027836 external-priority patent/WO2003022991A2/fr
Application filed by University of Texas System filed Critical University of Texas System
Publication of EP1546714A1 publication Critical patent/EP1546714A1/fr
Publication of EP1546714A4 publication Critical patent/EP1546714A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP02799873A 2002-08-30 2002-10-30 Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain Withdrawn EP1546714A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2002/027836 WO2003022991A2 (fr) 2001-09-07 2002-08-30 Compositions et procedes d'utilisation de peptides de ciblage contre les tissus adipeux et placentaires
WOPCT/US02/27836 2002-08-30
PCT/US2002/034987 WO2004020999A1 (fr) 2002-08-30 2002-10-30 Compositions et procedes d'utilisation de peptides de ciblage conçus pour le diagnostic et le traitement du cancer humain

Publications (2)

Publication Number Publication Date
EP1546714A1 EP1546714A1 (fr) 2005-06-29
EP1546714A4 true EP1546714A4 (fr) 2007-12-05

Family

ID=31975571

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02799873A Withdrawn EP1546714A4 (fr) 2002-08-30 2002-10-30 Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain

Country Status (4)

Country Link
EP (1) EP1546714A4 (fr)
AU (1) AU2002364501A1 (fr)
CA (1) CA2496938A1 (fr)
WO (1) WO2004020999A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322559A3 (fr) 2002-07-04 2011-08-03 Patrys Limited Anticorps specifiques de neoplasme et utilisations associees
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
EP1531162A1 (fr) 2003-11-14 2005-05-18 Heinz Vollmers Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
WO2005065418A2 (fr) * 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions et procedes d'utilisation de peptides de ciblage pour le diagnostic et la therapie
JP5479087B2 (ja) * 2006-04-07 2014-04-23 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム アデノ随伴ウイルスファージ粒子に関する方法および組成物
JP5374360B2 (ja) 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
WO2009155556A2 (fr) * 2008-06-20 2009-12-23 The Board Of Regents Of The University Of Texas System Peptides de ciblage de crkl
CN102120755B (zh) * 2010-04-23 2013-04-03 江苏省人民医院 一种棕色脂肪组织靶向性多肽及其应用
CN113278731A (zh) * 2021-05-12 2021-08-20 广西医科大学 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020822A2 (fr) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Biopanning et analyse rapide de ligands interactifs selectifs (brasil)
WO2002020769A1 (fr) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Peptides de ciblage humains et murins identifies par expression phagique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) * 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6093800A (en) * 1996-09-06 2000-07-25 The Regents Of The University Of California E25a protein, methods for production and use thereof
US6261789B1 (en) * 1997-03-10 2001-07-17 The Regents Of The University Of California Methods for detecting the presence of a PSCA protein using PSCA antibodies
US6372720B1 (en) * 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020822A2 (fr) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Biopanning et analyse rapide de ligands interactifs selectifs (brasil)
WO2002020769A1 (fr) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Peptides de ciblage humains et murins identifies par expression phagique
WO2002020724A2 (fr) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Ciblage adénoviral et manipulation de la réponse du système immunitaire au moyen de peptides ciblants
WO2002020723A2 (fr) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Compositions et procédés se rapporant à des peptides ciblants chez l'homme in vivo
WO2002020722A2 (fr) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas Syste Procedes et compositions utilises pour le ciblage in vitro

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004020999A1 *

Also Published As

Publication number Publication date
CA2496938A1 (fr) 2004-03-11
AU2002364501A1 (en) 2004-03-19
EP1546714A1 (fr) 2005-06-29
WO2004020999A1 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1571968A4 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
EP1589933A4 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
EP1478276A4 (fr) Nouvelles compositions ciblees destinees a une utilisation diagnostique et therapeutique
EP1515982A4 (fr) Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
EP1572091A4 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
EP1553912A4 (fr) Compositions et methodes pour le diagnostic et pour le traitement d'une tumeur
EP1578996A4 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
EP1551990A4 (fr) Diagnostic et traitement de tumeurs chimio-resistantes
EP1575571A4 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
EP1516049A4 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
EP1539251A4 (fr) Compositions et methodes permettant le diagnostic et le traitement d'etats pathologiques impliquant l'angiogenese
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1546714A4 (fr) Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain
EP1532162A4 (fr) Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
EP1420814A4 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003230849A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
GB0326578D0 (en) Cancer diagnosis and therapy
AU2003260301A8 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003279312A8 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003295902A8 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071105

17Q First examination report despatched

Effective date: 20080514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080925